GTN - definition, risk factor and management in MS obstetrics
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have sufficient data from authoritative textbooks to compile a comprehensive answer. Let me write it up:
Gestational Trophoblastic Neoplasia (GTN)
Definition
Gestational trophoblastic neoplasia (GTN) refers to the malignant subset of gestational trophoblastic disease (GTD) - a group of interrelated tumors arising from abnormal proliferation of placental trophoblasts with varying propensities for local invasion and metastasis.
GTD spectrum:
- Benign: Hydatidiform mole (complete and partial)
- Malignant (= GTN):
- Invasive mole
- Choriocarcinoma
- Placental-site trophoblastic tumor (PSTT)
- Epithelioid trophoblastic tumor (ETT)
GTN is one of the rare human malignancies curable even in the presence of widespread metastasis. GTN can occur after any gestational event - molar pregnancy, induced/spontaneous abortion, ectopic pregnancy, or term delivery.
- Berek & Novak's Gynecology, p. 2493
Risk Factors for GTN
1. Antecedent Pregnancy Type
GTN most commonly follows molar pregnancy but can occur after any pregnancy event. Risk by antecedent:
- Complete hydatidiform mole: 15-20% risk of persistent GTN
- Partial hydatidiform mole: 1-5% risk
- Non-molar pregnancies (term delivery, abortion): lower but real risk - Creasy & Resnik's Maternal-Fetal Medicine, p. 1356
2. High-Risk Features After Complete Mole
A review of 858 complete moles at the New England Trophoblastic Disease Center (NETDC) identified the following high-risk signs:
| High-Risk Sign | Prognostic Significance |
|---|---|
| hCG > 100,000 mIU/mL | Local invasion in 31%, metastasis in 8.8% of high-risk group |
| Excessive uterine enlargement | vs. local invasion only 3.4% in low-risk |
| Theca-lutein cysts ≥6 cm | Metastasis in 0.6% of low-risk group |
3. Age
- Older patients carry substantially higher risk
- Persistent GTN after complete mole: 37% in women >40 years, 60% in women >50 years
- Age >39 scores 1 point in the WHO Prognostic Scoring System
4. Other Epidemiological Risk Factors (for molar pregnancy leading to GTN)
-
Extremes of reproductive age
-
Prior molar pregnancy (risk of recurrent mole: 1-1.5% after one; rises after two)
-
History of prior miscarriage
-
Geographic/ethnic background (incidence highest in Asia: 2:1,000 in Japan; 1:1,500 in United States)
-
Berek & Novak's Gynecology, p. 2504, 2532; Creasy & Resnik's Maternal-Fetal Medicine, p. 1355-1356
Staging and Prognostic Scoring
FIGO Anatomic Staging
| Stage | Description |
|---|---|
| I | Confined to uterus |
| II | GTN extends outside uterus but limited to genital structures |
| III | GTN extends to lungs (with/without genital tract involvement) |
| IV | All other metastatic sites |
WHO Prognostic Scoring System (Modified)
Determines Low Risk (score <7) vs High Risk (score ≥7):
| Factor | 0 | 1 | 2 | 4 |
|---|---|---|---|---|
| Age (years) | ≤39 | >39 | - | - |
| Antecedent pregnancy | Hydatidiform mole | Abortion | Term | - |
| Interval to chemotherapy (months) | <4 | 4-6 | 7-12 | >12 |
| Pretreatment hCG (IU/L) | <10³ | 10³-10⁴ | 10⁴-10⁵ | >10⁵ |
| ABO blood group | - | O or A | B or AB | - |
| Largest tumor size (cm) | <3 | 3-5 | >5 | - |
| Site of metastases | - | Spleen, kidney | GI tract | Brain, liver |
| Number of metastases | - | 1-3 | 4-8 | >8 |
| Prior chemotherapy | - | - | 1 drug | ≥2 drugs |
- Berek & Novak's Gynecology, p. 2511
Diagnosis of GTN After Molar Evacuation
GTN is diagnosed biochemically when any of the following occur after molar evacuation:
- Plateau of hCG (±10% over 4 values across 3 weeks)
- Rise of hCG (>10% over 3 values across 2 weeks)
- Elevated hCG >6 months after evacuation
- Histologic diagnosis of choriocarcinoma
Diagnostic workup for confirmed GTN:
- Complete history and physical examination
- Serum hCG level
- Hepatic, thyroid, renal function tests
- CBC with differential
- Chest X-ray or CT chest
- Ultrasound or CT abdomen/pelvis
- CT/MRI brain (if metastatic disease or choriocarcinoma)
- Plasma-to-CSF hCG ratio: <60 suggests cerebral metastasis
Note on Phantom hCG: False-positive serum hCG from heterophilic antibodies can mimic GTN. Exclude by running a simultaneous urine hCG (these antibodies are not excreted in urine) or by serial dilution.
- Berek & Novak's Gynecology, p. 2511; Creasy & Resnik's Maternal-Fetal Medicine, p. 1356
Management of GTN
Protocol by Stage (Table 41-4, Berek & Novak's)
| Stage | Risk | Initial Treatment | Resistant Disease |
|---|---|---|---|
| Stage I | - | Single-agent chemo OR hysterectomy + adjuvant chemo | Combination chemo, hysterectomy, local resection, pelvic infusion |
| Stages II-III | Low (<7) | Single-agent chemo | Combination chemo |
| Stages II-III | High (≥7) | Combination chemo | Second-line combination chemo |
| Stage IV | - | Combination chemo | Second-line combination chemo, hepatic arterial infusion |
Low-Risk GTN (Stage I; Stages II-III, score <7)
Option 1 - Fertility desired:
- Single-agent chemotherapy - methotrexate (MTX) or actinomycin-D (Act-D)
- MTX regimens: 8-day MTX/folinic acid, weekly MTX IM, 5-day MTX
- Act-D: 5-day or pulsed regimen
- Remission rate with single-agent: very high (>80-90%)
Option 2 - Fertility not desired:
- Hysterectomy + adjuvant single-agent chemotherapy (concurrent, not sequential)
- Rationale: reduces viable cell dissemination at surgery, maintains cytotoxic levels, treats occult metastases
- In one NETDC series of 31 patients, 100% achieved complete remission with primary hysterectomy + single-agent chemo
PSTT and ETT (Stage I): Hysterectomy is preferred - these tumors are relatively chemoresistant
High-Risk GTN (Stages II-IV, score ≥7)
EMA-CO is the standard regimen:
- Etoposide
- Methotrexate
- Actinomycin-D
- Cyclophosphamide
- Oncovin (vincristine)
For brain metastases: Whole-brain radiation (3,000 cGy) + craniotomy if needed for complications
For liver metastases: Resection or embolization for complications
Post-Remission hCG Surveillance
- After molar evacuation: hCG weekly until normal x3 weeks, then monthly
- Standard surveillance: 6 months (shorter duration may be safe especially after partial mole, given risk of GTN after hCG becomes undetectable is ≤0.2%)
- Referral to gynecologic oncology if hCG plateaus, rises, or persists >6 months
Subsequent Pregnancies
GTN treatment does not impair future fertility:
- After complete mole (NETDC data, 1,388 pregnancies): 68.4% term births, 7.4% premature, 18.4% spontaneous abortion, 1.4% repeat molar pregnancy
- After GTN treated with chemotherapy (NETDC, 667 pregnancies): 66.9% term births, 18.4% spontaneous abortion - congenital malformation rate not increased despite chemotherapy exposure
Recommendations for subsequent pregnancies:
- First-trimester pelvic ultrasound to confirm normal development
- hCG level 6 weeks after delivery to exclude occult trophoblastic neoplasia
- Berek & Novak's Gynecology, p. 2521; Creasy & Resnik's Maternal-Fetal Medicine, p. 1356
Key Takeaway for MS Obstetrics: GTN is biochemically diagnosed by hCG monitoring after molar evacuation. The WHO prognostic score stratifies disease into low-risk (single-agent chemo) vs. high-risk (EMA-CO). Even metastatic disease carries excellent cure rates. Phantom hCG must be excluded. Subsequent reproductive outcomes are reassuring.
This is a shared conversation. Sign in to Orris to start your own chat.